Topics included:
• Current legal and political framework in Germany and the EU
• Integration of an ATMP into the statutory health insurance reimbursement 2024/25
• Gene/Cell Therapies from the Perspective : Health Insurance, Hospital, Industry
• Quality requirements for the application of ATMPs
• Challenges of the EU HTA
